In prostate cancer (PCa), ERG is the most overexpressed oncogene in patient tumour samples and the TMPRSS2‐ERG fusion, which can be formed by translocation or interstitial deletion, is a suspected driver of tumourigenesis in about 50% of prostate cancers [6, 7, 8]. This evidence concerns the gene TMPRSS2 and posterior cortical atrophy.